Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela; R. Jake Jacobs; Oscar Arteaga; Maria S. Navarrete; Allen S. Meyerhoff; Bruce L. Innis

doi:10.1016/j.vaccine.2005.03.021

Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

M. Teresa Valenzuela
, R. Jake Jacobs^*
, Oscar Arteaga
, Maria S. Navarrete
, Allen S. Meyerhoff
, Bruce L. Innis

^*Autor correspondiente de este trabajo

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

47 Citas (Scopus)

Resumen

Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

Idioma original	Inglés
Páginas (desde-hasta)	4110-4119
Número de páginas	10
Publicación	Vaccine
Volumen	23
N.º	32
DOI	https://doi.org/10.1016/j.vaccine.2005.03.021
Estado	Publicada - 14 jul. 2005
Publicado de forma externa	Sí

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1016/j.vaccine.2005.03.021

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{40645a7b5290401baa7facf214eb6cc3,

title = "Cost-effectiveness of universal childhood hepatitis A vaccination in Chile",

abstract = "Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80\%. Vaccination costs of US\$ 5.3-6.4 million would be offset by US\$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.",

keywords = "Cost and cost analysis, Hepatitis A, Vaccination",

author = "Valenzuela, \{M. Teresa\} and Jacobs, \{R. Jake\} and Oscar Arteaga and Navarrete, \{Maria S.\} and Meyerhoff, \{Allen S.\} and Innis, \{Bruce L.\}",

note = "Funding Information: We thank the following groups and individuals: the Ministry of Health, for supporting our access to data required to conduct this analysis; Dr. Betsy Hunter and Lorena Calabr{\'a}n, Hospital Luis Calvo Mackenna, for providing information on children with acute liver failure; the Infectious Disease Hospital, Hospital Lucio C{\'o}{\'o}rdoba, for assisting the cost analysis of adult patients; and CVD-Chile, for assisting the cost analysis of pediatric patients. This study was supported in part by an research grant from GlaxoSmithKline Biologicals to Capitol Outcomes Research Inc. Drs. Navarrete and Innis are employees of GlaxoSmithKline.",

year = "2005",

month = jul,

day = "14",

doi = "10.1016/j.vaccine.2005.03.021",

language = "English",

volume = "23",

pages = "4110--4119",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "32",

}

TY - JOUR

T1 - Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

AU - Valenzuela, M. Teresa

AU - Jacobs, R. Jake

AU - Arteaga, Oscar

AU - Navarrete, Maria S.

AU - Meyerhoff, Allen S.

AU - Innis, Bruce L.

N1 - Funding Information: We thank the following groups and individuals: the Ministry of Health, for supporting our access to data required to conduct this analysis; Dr. Betsy Hunter and Lorena Calabrán, Hospital Luis Calvo Mackenna, for providing information on children with acute liver failure; the Infectious Disease Hospital, Hospital Lucio Cóórdoba, for assisting the cost analysis of adult patients; and CVD-Chile, for assisting the cost analysis of pediatric patients. This study was supported in part by an research grant from GlaxoSmithKline Biologicals to Capitol Outcomes Research Inc. Drs. Navarrete and Innis are employees of GlaxoSmithKline.

PY - 2005/7/14

Y1 - 2005/7/14

N2 - Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

AB - Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination would reduce hepatitis A cases among birth cohort members and their personal contacts >80%. Vaccination costs of US$ 5.3-6.4 million would be offset by US$ 9.2-9.4 million reductions in disease costs. Further, approximately 70 fatal infections would be averted and >4600 quality-adjusted life years would be saved. This analysis supports the cost-effectiveness of universal childhood hepatitis A vaccination in Chile.

KW - Cost and cost analysis

KW - Hepatitis A

KW - Vaccination

UR - https://www.scopus.com/pages/publications/20444436017

U2 - 10.1016/j.vaccine.2005.03.021

DO - 10.1016/j.vaccine.2005.03.021

M3 - Article

C2 - 15964479

AN - SCOPUS:20444436017

SN - 0264-410X

VL - 23

SP - 4110

EP - 4119

JO - Vaccine

JF - Vaccine

IS - 32

ER -

Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto